SecBot SecBot
PRESS-RELEASE ·Filed Aug 6, 2026

PCRX

Pacira BioSciences
BULLISH
Impact 6/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The positive Phase 1 data and regulatory designations de-risk PCRX-201 to some extent, but the next major catalyst is the Phase 2 ASCEND topline readout expected year-end 2026. Investors should monitor enrollment updates and any interim data releases. The stock may see a modest positive reaction on this clinical milestone, but prolonged duration of effect (measured in years) would be a key differentiator from current therapies lasting 3-6 months.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$25.58
T+0 close · Aug 6, 2026 · via day close
Latest settled
+42.26%
T+60 · $36.39
Vs SPY
+43.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $25.58entry
  2. T+1 · 3mo ago −2.19%α −2.80% · $25.02
  3. T+5 · 3mo ago −9.38%α −10.60% · $23.18
  4. T+20 · 3mo ago +3.99%α +3.39% · $26.60
  5. T+60 · 18d ago +42.26%α +43.93% · $36.39

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pacira BioSciences reported positive two-year Phase 1 data for PCRX-201, a gene therapy for knee osteoarthritis, published in Annals of the Rheumatic Diseases. The single intra-articular injection was well tolerated and exploratory outcomes showed sustained improvements in pain, stiffness, and function across all doses. The Phase 2 ASCEND trial is ongoing with first topline readout expected by year-end 2026, and PCRX-201 has RMAT and ATMP regulatory designations.

Key Facts

  • Phase 1 data for PCRX-201 shows safety and exploratory efficacy through two years in moderate-to-severe knee OA
  • Results published in Annals of the Rheumatic Diseases, a top-tier rheumatology journal
  • Phase 2 ASCEND trial (Part B) enrollment initiated, with scalable manufacturing transitioned
  • PCRX-201 has received RMAT designation from FDA and ATMP designation from EMA
  • First topline Phase 2 data expected year-end 2026

Financial Impact

No near-term revenue impact; potential depends on Phase 2/3 success. Knee OA affects >15M US patients, representing a multi-billion-dollar market opportunity if PCRX-201 is approved.

pipeline valueregulatory catalysts

Risk Factors

  • Phase 2 ASCEND trial may fail to replicate Phase 1 findings
  • Manufacturing scale-up and cost of goods for gene therapy remain unproven at commercial scale
  • Competition from other non-opioid pain therapies and existing OA treatments
  • Regulatory hurdles for a novel gene therapy in a non-life-threatening condition

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3340186

Track record

29 reports on PCRX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +6.07% at T+60 after the Apr 13, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026